These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 12915343)

  • 1. Safety profile of levetiracetam.
    Arroyo S; Crawford P
    Epileptic Disord; 2003 May; 5 Suppl 1():S57-63. PubMed ID: 12915343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of levetiracetam in the treatment of epilepsy.
    Brodie MJ; French JA
    Epileptic Disord; 2003 May; 5 Suppl 1():S65-72. PubMed ID: 12915344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center.
    Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP
    Epilepsy Behav; 2007 Mar; 10(2):296-303. PubMed ID: 17317325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levetiracetam: preliminary efficacy in generalized seizures.
    Kasteleijn-Nolst Trenité DG; Hirsch E
    Epileptic Disord; 2003 May; 5 Suppl 1():S39-44. PubMed ID: 12915340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term experience with levetiracetam.
    Abou-Khalil B; Lazenby B
    Epileptic Disord; 2003 May; 5 Suppl 1():S33-7. PubMed ID: 12915339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levetiracetam: a new therapeutic option for refractory epilepsy.
    Pinto A; Sander JW
    Int J Clin Pract; 2003 Sep; 57(7):616-21. PubMed ID: 14529064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary efficacy of levetiracetam in monotherapy.
    Ben-Menachem E
    Epileptic Disord; 2003 May; 5 Suppl 1():S51-5. PubMed ID: 12915342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?
    Klitgaard H
    Epilepsia; 2001; 42 Suppl 4():13-8. PubMed ID: 11564119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study.
    Beran RG; Berkovic SF; Black AB; Danta G; Hiersemenzel R; Schapel GJ; Vajda FJ
    Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study.
    Callenbach PM; Arts WF; ten Houten R; Augustijn P; Gunning WB; Peeters EA; Weber AM; Stroink H; Geerts Y; Geerts AT; Brouwer OF
    Eur J Paediatr Neurol; 2008 Jul; 12(4):321-7. PubMed ID: 17950011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The SKATE study: interim analysis.
    Olwen GO
    Int J Clin Pract; 2003; 57(6):544-5. PubMed ID: 12918896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy.
    Li S; Cao J; Xiao N; Cai F
    J Child Neurol; 2010 May; 25(5):609-13. PubMed ID: 19779208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.
    Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I
    Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam.
    Kaminski RM; Matagne A; Patsalos PN; Klitgaard H
    Epilepsia; 2009 Mar; 50(3):387-97. PubMed ID: 18627416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open label, long-term, pragmatic study on levetiracetam in the treatment of juvenile myoclonic epilepsy.
    Specchio LM; Gambardella A; Giallonardo AT; Michelucci R; Specchio N; Boero G; La Neve A
    Epilepsy Res; 2006 Sep; 71(1):32-9. PubMed ID: 16814521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levetiracetam in a broad population of patients with refractory epilepsy: interim results of the international SKATE trial.
    Genton P; Sadzot B; Fejerman N; Peltola J; Despland PA; Steinhoff B; Rektor I; Wroe S; Maubrey MC; Vandervelden C; van Hammée G; Schlit AF; van Paesschen W
    Acta Neurol Scand; 2006 Jun; 113(6):387-94. PubMed ID: 16674605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acceptability and tolerability of levetiracetam oral solution for the treatment of partial-onset seizures: the SOLUCIÓN study.
    Matías-Guíu J; Molins A; Mauri JA; Villar E
    Methods Find Exp Clin Pharmacol; 2010 Sep; 32(7):507-16. PubMed ID: 21069102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures.
    Wu XY; Hong Z; Wu X; Wu LW; Wang XF; Zhou D; Zhao ZX; Lv CZ
    Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levetiracetam: a long-term follow-up study of efficacy and safety.
    Bauer J; Ben-Menachem E; Krämer G; Fryze W; Da Silva S; Kasteleijn-Nolst Trenité DG
    Acta Neurol Scand; 2006 Sep; 114(3):169-76. PubMed ID: 16911344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of paradoxical levetiracetam effect is increased in mentally retarded patients.
    Szucs A; Clemens Z; Jakus R; Rásonyi G; Fabó D; Holló A; Barcs G; Kelemen A; Janszky J
    Epilepsia; 2008 Jul; 49(7):1174-9. PubMed ID: 18479387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.